SCHEMBL4528519

SCHEMBL4528519

O=C(O)CCCCCCCCCCCCS

nearest known ligand 0.94

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 2/20 0.94
TSHR P16473 5/20 0.71
LMNA P02545 3/20 0.71
NFKB1 P19838 1/20 0.71
PMP22 Q01453 1/20 0.71
GPR84 Q9NQS5 7/20 0.57
FFAR1 O14842 2/20 0.57
FFAR4 Q5NUL3 2/20 0.57
SLC22A6 Q4U2R8 2/20 0.56
PPARG P37231 6/20 0.55
PPARD Q03181 6/20 0.55
PPARA Q07869 6/20 0.55
HDAC11 Q96DB2 5/20 0.55
ALDH1A1 P00352 3/20 0.55
TLR2 O60603 2/20 0.55
TDP1 Q9NUW8 2/20 0.55
MEN1 O00255 2/20 0.55
FABP4 P15090 2/20 0.55
ALOX15 P16050 2/20 0.55
PTPN1 P18031 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2837455 1.00 FOLH1 (0.94) FOLH1TSHRLMNANFKB1PMP22
SCHEMBL4521988 1.00 FOLH1 (0.94) FOLH1TSHRLMNANFKB1PMP22
SCHEMBL4538714 1.00 FOLH1 (0.94) FOLH1TSHRLMNANFKB1PMP22
SCHEMBL4531504 1.00 FOLH1 (0.94) FOLH1TSHRLMNANFKB1PMP22
SCHEMBL4533686 1.00 FOLH1 (0.94) FOLH1TSHRLMNANFKB1PMP22
SCHEMBL202758 1.00 FOLH1 (0.94) FOLH1TSHRLMNANFKB1PMP22
SCHEMBL4533669 1.00 FOLH1 (0.94) FOLH1TSHRLMNANFKB1PMP22
SCHEMBL173209 1.00
SCHEMBL4536912 1.00 FOLH1 (0.94) FOLH1TSHRLMNANFKB1PMP22
SCHEMBL1954234 1.00 FOLH1 (0.94) FOLH1TSHRLMNANFKB1PMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118895120-A Optical material for anti-counterfeit label, preparation method thereof and anti-counterfeit label 兰州大学 2024-11-05 CN claimed
CN-116271074-A Tumor targeting therapeutic drug with dual therapeutic mechanism 东曜药业有限公司 2023-06-23 CN claimed
US-20170087640-A1 PHOTOLUMINESCENT GOLD NANOPARTICLES AND MANUFACTURING METHOD THEREOF HWU, YEU-KUANG (TW) 2017-03-30 US claimed
CN-118895120-A Optical material for anti-counterfeit label, preparation method thereof and anti-counterfeit label 兰州大学 2024-11-05 CN disclosed
CN-116271074-B Tumor targeting therapeutic drug with dual therapeutic mechanism 东曜药业有限公司 2023-08-25 CN disclosed
CN-116271074-A Tumor targeting therapeutic drug with dual therapeutic mechanism 东曜药业有限公司 2023-06-23 CN disclosed
EP-4188984-A1 VIRUCIDAL COMPOSITIONS AND USE THEREOF ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) 2023-06-07 EP disclosed
US-20230165891-A1 VIRUCIDAL COMPOSITIONS AND USE THEREOF ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (CH) 2023-06-01 US disclosed
WO-2022023335-A1 VIRUCIDAL COMPOSITIONS AND USE THEREOF ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) 2022-02-03 WO disclosed
EP-2862936-B1 OXIDOREDUCTASE REACTION CONTROL USING AMINO SUBSTITUTED BIPYRIDINIUM COMPOUNDS AMANO ENZYME INC (JP) 2021-12-22 EP disclosed
US-9777299-B2 Oxidoreductase reaction control and use thereof AMANO ENZYME INC. (JP) 2017-10-03 US disclosed
US-20170087640-A1 PHOTOLUMINESCENT GOLD NANOPARTICLES AND MANUFACTURING METHOD THEREOF HWU, YEU-KUANG (TW) 2017-03-30 US disclosed
US-9378962-B2 Nonvolatile semiconductor storage device having a charge storage layer that includes metal grains KABUSHIKI KAISHA TOSHIBA (JP) 2016-06-28 US disclosed
US-20150176037-A1 OXIDOREDUCTASE REACTION CONTROL AND USE THEREOF AMANO ENZYME INC. (JP) 2015-06-25 US disclosed
EP-2862936-A1 OXIDOREDUCTASE REACTION CONTROL AND USE THEREOF Amano Enzyme Inc. (JP) 2015-04-22 EP disclosed
US-20130242670-A1 NONVOLATILE SEMICONDUCTOR STORAGE DEVICE KABUSHIKI KAISHA TOSHIBA (JP) 2013-09-19 US disclosed
US-20090123516-A1 DRUG DELIVERY FROM IMPLANTS USING SELF-ASSEMBLED MONOLAYERS-THERAPEUTIC SAMS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2009-05-14 US disclosed
WO-2007019478-A2 DRUG DELIVERY FROM IMPLANTS USING SELF-ASSEMBLED MONOLAYERS - THERAPEUTIC SAMS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230165891-A1 VIRUCIDAL COMPOSITIONS AND USE THEREOF SELPLG, DDOST, CD2BP2 FOLH1 1788/4885TSHR 4521/4885LMNA 2975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.